- Home
- HSDT vs SILO Comparison
HSDT vs SILO Comparison
Compare HSDT & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- SILO
- Stock Information
- Founded
- HSDT N/A
- SILO 2010
- Country
- HSDT United States
- SILO United States
- Employees
- HSDT N/A
- SILO N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SILO Apparel
- Sector
- HSDT Health Care
- SILO Consumer Discretionary
- Exchange
- HSDT Nasdaq
- SILO Nasdaq
- Market Cap
- HSDT 6.4M
- SILO 5.9M
- IPO Year
- HSDT N/A
- SILO N/A
- Fundamental
- Price
- HSDT $22.75
- SILO $0.70
- Analyst Decision
- HSDT Hold
- SILO
- Analyst Count
- HSDT 1
- SILO 0
- Target Price
- HSDT N/A
- SILO N/A
- AVG Volume (30 Days)
- HSDT 1.2M
- SILO 941.5K
- Earning Date
- HSDT 11-11-2025
- SILO 11-11-2025
- Dividend Yield
- HSDT N/A
- SILO N/A
- EPS Growth
- HSDT N/A
- SILO N/A
- EPS
- HSDT N/A
- SILO N/A
- Revenue
- HSDT $295,000.00
- SILO $72,102.00
- Revenue This Year
- HSDT N/A
- SILO $1.86
- Revenue Next Year
- HSDT $75.13
- SILO N/A
- P/E Ratio
- HSDT N/A
- SILO N/A
- Revenue Growth
- HSDT N/A
- SILO N/A
- 52 Week Low
- HSDT $5.37
- SILO $0.41
- 52 Week High
- HSDT $1,200.00
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- HSDT 86.15
- SILO 54.08
- Support Level
- HSDT $5.78
- SILO $0.58
- Resistance Level
- HSDT $24.49
- SILO $0.83
- Average True Range (ATR)
- HSDT 1.62
- SILO 0.05
- MACD
- HSDT 2.35
- SILO 0.01
- Stochastic Oscillator
- HSDT 90.70
- SILO 48.39
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.